WENTWORTH KORY JAMES (CIK 1725663) reported 13 SEC Form 4 insider transactions across 1 companies over the past 18 months (most recent 2026-04-02). Recent activity: Sell TRDA (2,500 shares), Sell TRDA (5,089 shares), Sell TRDA (11,388 shares), Sell TRDA (7,988 shares), Buy TRDA (44,600 shares). Source: SEC Form 4.
| Date | Company | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-02 | Entrada Therapeutics, Inc. (TRDA) | Chief Financial Officer | Sell | 2,500 | $32,375 |
| 2026-03-11 | Entrada Therapeutics, Inc. (TRDA) | Chief Financial Officer | Sell | 5,089 | $66,157 |
| 2026-03-11 | Entrada Therapeutics, Inc. (TRDA) | Chief Financial Officer | Sell | 11,388 | $148,272 |
| 2026-03-06 | Entrada Therapeutics, Inc. (TRDA) | Chief Financial Officer | Sell | 7,988 | $97,853 |
| 2026-03-03 | Entrada Therapeutics, Inc. (TRDA) | Chief Financial Officer | Buy | 44,600 | $0 |
| 2026-03-03 | Entrada Therapeutics, Inc. (TRDA) | Chief Financial Officer | Sell | 2,939 | $34,269 |
| 2026-03-03 | Entrada Therapeutics, Inc. (TRDA) | Chief Financial Officer | Sell | 5,712 | $67,173 |
| 2025-11-24 | Entrada Therapeutics, Inc. (TRDA) | Chief Financial Officer | Sell | 8,910 | $88,922 |
| 2025-09-04 | Entrada Therapeutics, Inc. (TRDA) | Chief Financial Officer | Sell | 1,734 | $9,416 |
| 2025-04-04 | Entrada Therapeutics, Inc. (TRDA) | Chief Financial Officer | Buy | 11,134 | $23,381 |
| 2025-03-19 | Entrada Therapeutics, Inc. (TRDA) | Chief Financial Officer | Sell | 1,784 | $19,035 |
| 2025-03-04 | Entrada Therapeutics, Inc. (TRDA) | Chief Financial Officer | Buy | 42,400 | $0 |
| 2025-03-04 | Entrada Therapeutics, Inc. (TRDA) | Chief Financial Officer | Sell | 4,929 | $57,571 |
Source: SEC Form 4 filings · as of 2026-04-02